Medical Implant Market By Product (Orthopedic implants, Cardiovascular Implants, Spinal Implants, Neurostimulators, Opthalmic Implants, Dental Implants, Facial Implants, Breast implants) , By Biomaterial Type (Metallic Biomaterials , Ceramic Biomaterials , Polymers Biomaterials , Natural Biomaterials) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The medical implant market was valued at $112.8 billion in 2023, and is projected t%li%reach $225.7 billion by 2033, growing at a CAGR of 7.2% from 2024 t%li%2033.
Medical implant is a medical device or tissue that is placed inside or on the surface of the body t%li%replace mimic the functions of biological structures in individuals whose organs are damaged, dysfunctional, or impaired. They are used t%li%restore function and provide support in patients suffering from various medical conditions or injuries. They can be made from a variety of materials, including metals, ceramics, polymers, and biological tissues. Various types of implants include orthopedic, cardiovascular, neurological, dental, ophthalmic, cochlear, and cosmetic implants.
The growth of the global medical implant market is majorly driven by alarming increase in prevalence of chronic conditions such as cardiovascular diseases, diabetes, and neurological disorders necessitates the use of implants for treatment and management, such as pacemakers, stents, and neurostimulators. Moreover, rise in geriatric population acts as a key driving force of the global market. This is attributed t%li%the fact that increase in elderly population leads t%li%a higher prevalence of age-related conditions such as osteoporosis, cardiovascular diseases, and degenerative joint diseases, boosting the demand for medical implants. Furthermore, rise in accidents, sports injuries, and trauma cases leads t%li%higher demand for orthopedic implants t%li%repair and support damaged bones and joints. Thus, these facts determine that orthopedic implants are considered the most common. According t%li%an article published by Wolters Kluwer, a Dutch information services company, almost tw%li%million bone grafting procedures are performed worldwide per year. Among these, 500,000 bone graft are performed annually in the U.S. alone. Furthermore, increase in awareness among patients and healthcare providers about the benefits of medical implants and enhanced healthcare facilities and infrastructure in developing regions increase access t%li%advanced medical treatments, including implant surgeries, boost the market growth. Desire for improved physical appearance has significantly propelled the demand for cosmetic surgeries and procedures, such as breast implants and facial implants, further augmenting the market growth. Growing trend of medical tourism, where patients travel t%li%other countries for affordable and high-quality implant procedures, considerably contributes toward the market growth. According t%li%Medical Tourism Association—a non-profit organization in Florida that focuses on raising awareness for medical travel while driving the adoption of affordable and transparent medical practices—approximately 14 million individuals travel t%li%other countries in search of medical care annually across the world, garnering between 50 and 70 thousand million dollars. However, high cost associated with development, production, and implementation of advanced medical implants hampers the growth of the market. Moreover, lack of appropriate health facilities t%li%meet population needs in most countries and limited access act as the key deterrent factors of the market. Furthermore, risk of immune rejection and ethical conflicts significantly restrain the market growth. On the contrary, continuous innovations in implant materials, design, and surgical techniques t%li%improve the safety, effectiveness, and longevity of medical implants are expected t%li%offer lucrative opportunities for the market growth during the forecast period. For instance, manufacturers are focusing on the development of implants made from biodegradable materials that gradually dissolve in the body, thus eliminating the need for surgical removal and reducing long-term complications.
The global medical implant market is segmented int%li%product, biomaterial type, and region. On the basis of product, the market is fragmented int%li%orthopedic implants, cardiovascular implants, spinal implants, neurostimulators, ophthalmic implants, dental implants, facial implants, and breast implants. Depending on biomaterial type, it is categorized int%li%metallic biomaterials, ceramic biomaterials, polymers biomaterials, and natural biomaterials. Region wise, it is analyzed across North America, Europe, Asia-Pacific, LAMEA.
Key Findings
By product, the orthopedic implants segment dominated the market, in terms of share, in 2023.
Depending on biomaterial type, metallic biomaterials emerged as the leading segment in 2023.
Region wise, North America was the major shareholder in 2023.
Competition Analysis
Competitive analysis and profiles of the major players in the global medical implant market include Biotronik, Boston Scientific Corporation, CONMED Corporation, Globus Medical, Inc., Institut Straumann AG, Integra LifeSciences Holdings Corporation, LivaNova PLC, Medtronic plc, NuVasive, Inc., and Johnson & Johnson. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships t%li%gain a strong foothold and sustain the intense competition.
Additional benefits you will get with this purchase are:
By Product
? Hip Replacement Implants
? Extremities
? Implantable Cardioverter Defibrillators (ICDs)
? Implantable Cardiac Pacemakers (ICPs)
? Peripheral stents
? Stent-related Implants
? Implantable Ventricular-assist Devices
Medical implant is a medical device or tissue that is placed inside or on the surface of the body t%li%replace mimic the functions of biological structures in individuals whose organs are damaged, dysfunctional, or impaired. They are used t%li%restore function and provide support in patients suffering from various medical conditions or injuries. They can be made from a variety of materials, including metals, ceramics, polymers, and biological tissues. Various types of implants include orthopedic, cardiovascular, neurological, dental, ophthalmic, cochlear, and cosmetic implants.
The growth of the global medical implant market is majorly driven by alarming increase in prevalence of chronic conditions such as cardiovascular diseases, diabetes, and neurological disorders necessitates the use of implants for treatment and management, such as pacemakers, stents, and neurostimulators. Moreover, rise in geriatric population acts as a key driving force of the global market. This is attributed t%li%the fact that increase in elderly population leads t%li%a higher prevalence of age-related conditions such as osteoporosis, cardiovascular diseases, and degenerative joint diseases, boosting the demand for medical implants. Furthermore, rise in accidents, sports injuries, and trauma cases leads t%li%higher demand for orthopedic implants t%li%repair and support damaged bones and joints. Thus, these facts determine that orthopedic implants are considered the most common. According t%li%an article published by Wolters Kluwer, a Dutch information services company, almost tw%li%million bone grafting procedures are performed worldwide per year. Among these, 500,000 bone graft are performed annually in the U.S. alone. Furthermore, increase in awareness among patients and healthcare providers about the benefits of medical implants and enhanced healthcare facilities and infrastructure in developing regions increase access t%li%advanced medical treatments, including implant surgeries, boost the market growth. Desire for improved physical appearance has significantly propelled the demand for cosmetic surgeries and procedures, such as breast implants and facial implants, further augmenting the market growth. Growing trend of medical tourism, where patients travel t%li%other countries for affordable and high-quality implant procedures, considerably contributes toward the market growth. According t%li%Medical Tourism Association—a non-profit organization in Florida that focuses on raising awareness for medical travel while driving the adoption of affordable and transparent medical practices—approximately 14 million individuals travel t%li%other countries in search of medical care annually across the world, garnering between 50 and 70 thousand million dollars. However, high cost associated with development, production, and implementation of advanced medical implants hampers the growth of the market. Moreover, lack of appropriate health facilities t%li%meet population needs in most countries and limited access act as the key deterrent factors of the market. Furthermore, risk of immune rejection and ethical conflicts significantly restrain the market growth. On the contrary, continuous innovations in implant materials, design, and surgical techniques t%li%improve the safety, effectiveness, and longevity of medical implants are expected t%li%offer lucrative opportunities for the market growth during the forecast period. For instance, manufacturers are focusing on the development of implants made from biodegradable materials that gradually dissolve in the body, thus eliminating the need for surgical removal and reducing long-term complications.
The global medical implant market is segmented int%li%product, biomaterial type, and region. On the basis of product, the market is fragmented int%li%orthopedic implants, cardiovascular implants, spinal implants, neurostimulators, ophthalmic implants, dental implants, facial implants, and breast implants. Depending on biomaterial type, it is categorized int%li%metallic biomaterials, ceramic biomaterials, polymers biomaterials, and natural biomaterials. Region wise, it is analyzed across North America, Europe, Asia-Pacific, LAMEA.
Key Findings
By product, the orthopedic implants segment dominated the market, in terms of share, in 2023.
Depending on biomaterial type, metallic biomaterials emerged as the leading segment in 2023.
Region wise, North America was the major shareholder in 2023.
Competition Analysis
Competitive analysis and profiles of the major players in the global medical implant market include Biotronik, Boston Scientific Corporation, CONMED Corporation, Globus Medical, Inc., Institut Straumann AG, Integra LifeSciences Holdings Corporation, LivaNova PLC, Medtronic plc, NuVasive, Inc., and Johnson & Johnson. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships t%li%gain a strong foothold and sustain the intense competition.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting t%li%16 analyst hours t%li%solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent t%li%3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
- Additional company profiles with specific t%li%client's interest
- Additional country or region analysis- market size and forecast
- Average Selling Price Analysis / Price Point Analysis
- Criss-cross segment analysis- market size and forecast
- Historic market data
- Import Export Analysis/Data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- Market share analysis of players at global/region/country level
By Product
- Orthopedic implants
- Reconstructive Joint Replacements
? Hip Replacement Implants
? Extremities
- Orthobiologics
- Trauma and Craniomaxillofacial
- Cardiovascular Implants
- Pacing Devices
? Implantable Cardioverter Defibrillators (ICDs)
? Implantable Cardiac Pacemakers (ICPs)
- Stents
? Peripheral stents
? Stent-related Implants
- Structural Cardiac Implants
? Implantable Ventricular-assist Devices
- Spinal Implants
- Spinal fusion implants
- Spinal bone stimulators
- Vertebral Compression Fracture (VCF) Devices
- Motion Preservation Devices/Non-Fusion Devices
- Neurostimulators
- Deep Brain Stimulation
- Sacral Nerve Stimulation
- Vagus Nerve Stimulation
- Spinal Cord Stimulation
- Other neurostimulators
- Opthalmic Implants
- Intraocular Lens
- Glaucoma Implants
- Dental Implants
- Plate Form Dental Implants
- Root Form Dental Implants
- Facial Implants
- Breast implants
- Metallic Biomaterials
- Ceramic Biomaterials
- Polymers Biomaterials
- Natural Biomaterials
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
- Key Market Players
- Biotronik
- Boston Scientific Corporation
- CONMED Corporation
- Globus Medical, Inc.
- Institut Straumann AG
- Integra LifeSciences Holdings Corporation
- LivaNova PLC
- Medtronic plc
- NuVasive, Inc.
- Johnson & Johnson
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS
4.1. Market Overview
4.1.1 Market Size and Forecast, By Drug Class
4.2. Chemotherapy
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Targeted Therapy
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Immunotherapy (Biologic Therapy)
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Hormonal Therapy
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
CHAPTER 5: ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Indication
5.2. Lung Cancer
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Stomach Cancer
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Colorectal Cancer
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
5.5. Breast Cancer
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, By Region
5.5.3. Market Share Analysis, By Country
5.6. Prostate Cancer
5.6.1. Key Market Trends, Growth Factors and Opportunities
5.6.2. Market Size and Forecast, By Region
5.6.3. Market Share Analysis, By Country
5.7. Liver Cancer
5.7.1. Key Market Trends, Growth Factors and Opportunities
5.7.2. Market Size and Forecast, By Region
5.7.3. Market Share Analysis, By Country
5.8. Esophagus Cancer
5.8.1. Key Market Trends, Growth Factors and Opportunities
5.8.2. Market Size and Forecast, By Region
5.8.3. Market Share Analysis, By Country
5.9. Cervical Cancer
5.9.1. Key Market Trends, Growth Factors and Opportunities
5.9.2. Market Size and Forecast, By Region
5.9.3. Market Share Analysis, By Country
5.10. Kidney Cancer
5.10.1. Key Market Trends, Growth Factors and Opportunities
5.10.2. Market Size and Forecast, By Region
5.10.3. Market Share Analysis, By Country
5.11. Bladder Cancer
5.11.1. Key Market Trends, Growth Factors and Opportunities
5.11.2. Market Size and Forecast, By Region
5.11.3. Market Share Analysis, By Country
5.12. Other Cancers
5.12.1. Key Market Trends, Growth Factors and Opportunities
5.12.2. Market Size and Forecast, By Region
5.12.3. Market Share Analysis, By Country
CHAPTER 6: ONCOLOGY-CANCER DRUGS MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Drug Class
6.2.3. Market Size and Forecast, By Indication
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Oncology-Cancer Drugs Market
6.2.5.1. Market Size and Forecast, By Drug Class
6.2.5.2. Market Size and Forecast, By Indication
6.2.6. Canada Oncology-Cancer Drugs Market
6.2.6.1. Market Size and Forecast, By Drug Class
6.2.6.2. Market Size and Forecast, By Indication
6.2.7. Mexico Oncology-Cancer Drugs Market
6.2.7.1. Market Size and Forecast, By Drug Class
6.2.7.2. Market Size and Forecast, By Indication
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Drug Class
6.3.3. Market Size and Forecast, By Indication
6.3.4. Market Size and Forecast, By Country
6.3.5. Germany Oncology-Cancer Drugs Market
6.3.5.1. Market Size and Forecast, By Drug Class
6.3.5.2. Market Size and Forecast, By Indication
6.3.6. France Oncology-Cancer Drugs Market
6.3.6.1. Market Size and Forecast, By Drug Class
6.3.6.2. Market Size and Forecast, By Indication
6.3.7. UK Oncology-Cancer Drugs Market
6.3.7.1. Market Size and Forecast, By Drug Class
6.3.7.2. Market Size and Forecast, By Indication
6.3.8. Italy Oncology-Cancer Drugs Market
6.3.8.1. Market Size and Forecast, By Drug Class
6.3.8.2. Market Size and Forecast, By Indication
6.3.9. Spain Oncology-Cancer Drugs Market
6.3.9.1. Market Size and Forecast, By Drug Class
6.3.9.2. Market Size and Forecast, By Indication
6.3.10. Rest of Europe Oncology-Cancer Drugs Market
6.3.10.1. Market Size and Forecast, By Drug Class
6.3.10.2. Market Size and Forecast, By Indication
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Drug Class
6.4.3. Market Size and Forecast, By Indication
6.4.4. Market Size and Forecast, By Country
6.4.5. China Oncology-Cancer Drugs Market
6.4.5.1. Market Size and Forecast, By Drug Class
6.4.5.2. Market Size and Forecast, By Indication
6.4.6. Japan Oncology-Cancer Drugs Market
6.4.6.1. Market Size and Forecast, By Drug Class
6.4.6.2. Market Size and Forecast, By Indication
6.4.7. India Oncology-Cancer Drugs Market
6.4.7.1. Market Size and Forecast, By Drug Class
6.4.7.2. Market Size and Forecast, By Indication
6.4.8. Australia Oncology-Cancer Drugs Market
6.4.8.1. Market Size and Forecast, By Drug Class
6.4.8.2. Market Size and Forecast, By Indication
6.4.9. South Korea Oncology-Cancer Drugs Market
6.4.9.1. Market Size and Forecast, By Drug Class
6.4.9.2. Market Size and Forecast, By Indication
6.4.10. Rest of Asia-Pacific Oncology-Cancer Drugs Market
6.4.10.1. Market Size and Forecast, By Drug Class
6.4.10.2. Market Size and Forecast, By Indication
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Drug Class
6.5.3. Market Size and Forecast, By Indication
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Oncology-Cancer Drugs Market
6.5.5.1. Market Size and Forecast, By Drug Class
6.5.5.2. Market Size and Forecast, By Indication
6.5.6. South Africa Oncology-Cancer Drugs Market
6.5.6.1. Market Size and Forecast, By Drug Class
6.5.6.2. Market Size and Forecast, By Indication
6.5.7. Saudi Arabia Oncology-Cancer Drugs Market
6.5.7.1. Market Size and Forecast, By Drug Class
6.5.7.2. Market Size and Forecast, By Indication
6.5.8. Rest of LAMEA Oncology-Cancer Drugs Market
6.5.8.1. Market Size and Forecast, By Drug Class
6.5.8.2. Market Size and Forecast, By Indication
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. AbbVie Inc.
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Amgen
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Astellas Pharma Inc.
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. AstraZeneca Plc
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Bristol-Myers Squibb Company
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. F. Hoffmann-La Roche Ltd.
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Johnson And Johnson
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Merck And Co., Inc.
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Novartis AG
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Pfizer Inc.
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS
4.1. Market Overview
4.1.1 Market Size and Forecast, By Drug Class
4.2. Chemotherapy
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Targeted Therapy
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Immunotherapy (Biologic Therapy)
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Hormonal Therapy
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
CHAPTER 5: ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Indication
5.2. Lung Cancer
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Stomach Cancer
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Colorectal Cancer
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
5.5. Breast Cancer
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, By Region
5.5.3. Market Share Analysis, By Country
5.6. Prostate Cancer
5.6.1. Key Market Trends, Growth Factors and Opportunities
5.6.2. Market Size and Forecast, By Region
5.6.3. Market Share Analysis, By Country
5.7. Liver Cancer
5.7.1. Key Market Trends, Growth Factors and Opportunities
5.7.2. Market Size and Forecast, By Region
5.7.3. Market Share Analysis, By Country
5.8. Esophagus Cancer
5.8.1. Key Market Trends, Growth Factors and Opportunities
5.8.2. Market Size and Forecast, By Region
5.8.3. Market Share Analysis, By Country
5.9. Cervical Cancer
5.9.1. Key Market Trends, Growth Factors and Opportunities
5.9.2. Market Size and Forecast, By Region
5.9.3. Market Share Analysis, By Country
5.10. Kidney Cancer
5.10.1. Key Market Trends, Growth Factors and Opportunities
5.10.2. Market Size and Forecast, By Region
5.10.3. Market Share Analysis, By Country
5.11. Bladder Cancer
5.11.1. Key Market Trends, Growth Factors and Opportunities
5.11.2. Market Size and Forecast, By Region
5.11.3. Market Share Analysis, By Country
5.12. Other Cancers
5.12.1. Key Market Trends, Growth Factors and Opportunities
5.12.2. Market Size and Forecast, By Region
5.12.3. Market Share Analysis, By Country
CHAPTER 6: ONCOLOGY-CANCER DRUGS MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Drug Class
6.2.3. Market Size and Forecast, By Indication
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Oncology-Cancer Drugs Market
6.2.5.1. Market Size and Forecast, By Drug Class
6.2.5.2. Market Size and Forecast, By Indication
6.2.6. Canada Oncology-Cancer Drugs Market
6.2.6.1. Market Size and Forecast, By Drug Class
6.2.6.2. Market Size and Forecast, By Indication
6.2.7. Mexico Oncology-Cancer Drugs Market
6.2.7.1. Market Size and Forecast, By Drug Class
6.2.7.2. Market Size and Forecast, By Indication
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Drug Class
6.3.3. Market Size and Forecast, By Indication
6.3.4. Market Size and Forecast, By Country
6.3.5. Germany Oncology-Cancer Drugs Market
6.3.5.1. Market Size and Forecast, By Drug Class
6.3.5.2. Market Size and Forecast, By Indication
6.3.6. France Oncology-Cancer Drugs Market
6.3.6.1. Market Size and Forecast, By Drug Class
6.3.6.2. Market Size and Forecast, By Indication
6.3.7. UK Oncology-Cancer Drugs Market
6.3.7.1. Market Size and Forecast, By Drug Class
6.3.7.2. Market Size and Forecast, By Indication
6.3.8. Italy Oncology-Cancer Drugs Market
6.3.8.1. Market Size and Forecast, By Drug Class
6.3.8.2. Market Size and Forecast, By Indication
6.3.9. Spain Oncology-Cancer Drugs Market
6.3.9.1. Market Size and Forecast, By Drug Class
6.3.9.2. Market Size and Forecast, By Indication
6.3.10. Rest of Europe Oncology-Cancer Drugs Market
6.3.10.1. Market Size and Forecast, By Drug Class
6.3.10.2. Market Size and Forecast, By Indication
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Drug Class
6.4.3. Market Size and Forecast, By Indication
6.4.4. Market Size and Forecast, By Country
6.4.5. China Oncology-Cancer Drugs Market
6.4.5.1. Market Size and Forecast, By Drug Class
6.4.5.2. Market Size and Forecast, By Indication
6.4.6. Japan Oncology-Cancer Drugs Market
6.4.6.1. Market Size and Forecast, By Drug Class
6.4.6.2. Market Size and Forecast, By Indication
6.4.7. India Oncology-Cancer Drugs Market
6.4.7.1. Market Size and Forecast, By Drug Class
6.4.7.2. Market Size and Forecast, By Indication
6.4.8. Australia Oncology-Cancer Drugs Market
6.4.8.1. Market Size and Forecast, By Drug Class
6.4.8.2. Market Size and Forecast, By Indication
6.4.9. South Korea Oncology-Cancer Drugs Market
6.4.9.1. Market Size and Forecast, By Drug Class
6.4.9.2. Market Size and Forecast, By Indication
6.4.10. Rest of Asia-Pacific Oncology-Cancer Drugs Market
6.4.10.1. Market Size and Forecast, By Drug Class
6.4.10.2. Market Size and Forecast, By Indication
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Drug Class
6.5.3. Market Size and Forecast, By Indication
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Oncology-Cancer Drugs Market
6.5.5.1. Market Size and Forecast, By Drug Class
6.5.5.2. Market Size and Forecast, By Indication
6.5.6. South Africa Oncology-Cancer Drugs Market
6.5.6.1. Market Size and Forecast, By Drug Class
6.5.6.2. Market Size and Forecast, By Indication
6.5.7. Saudi Arabia Oncology-Cancer Drugs Market
6.5.7.1. Market Size and Forecast, By Drug Class
6.5.7.2. Market Size and Forecast, By Indication
6.5.8. Rest of LAMEA Oncology-Cancer Drugs Market
6.5.8.1. Market Size and Forecast, By Drug Class
6.5.8.2. Market Size and Forecast, By Indication
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. AbbVie Inc.
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Amgen
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Astellas Pharma Inc.
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. AstraZeneca Plc
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Bristol-Myers Squibb Company
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. F. Hoffmann-La Roche Ltd.
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Johnson And Johnson
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Merck And Co., Inc.
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Novartis AG
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Pfizer Inc.
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
